Standout Papers

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid c... 2014 2026 2018 2022 1.1k
  1. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014)
    Marcia S. Brose, Christopher M. Nutting et al. The Lancet

Immediate Impact

2 from Science/Nature 106 standout
Sub-graph 1 of 13

Citing Papers

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
20 intermediate papers

Works of John Chung being referenced

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
2014 Standout
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
2004
and 4 more

Author Peers

Author Last Decade Papers Cites
John Chung 1043 323 40 472 14 1.5k
Begoña de las Heras 964 311 25 596 27 1.7k
Agnese Biagini 1087 445 21 358 15 1.4k
István Molnár 991 452 25 555 43 2.0k
Yifah Yaron 610 328 57 608 17 1.3k
Jessica Read 743 420 44 723 11 1.6k
Tihana Ibrahimpašić 1433 475 8 558 13 1.8k
Yu-Nien Sun 514 526 34 560 12 1.3k
Hyeyeun Lim 1215 243 7 336 19 1.6k
Barbara Cosci 1051 296 64 385 14 1.3k
Guangwu Zhu 1153 609 8 427 16 1.5k

All Works

Loading papers...

Rankless by CCL
2026